Prognostic value of GRIM-19, NF-kappa B and IKK2 in patients with high-grade serous ovarian cancer

Prognostic value of GRIM-19, NF-kappa B and IKK2 in patients with high-grade serous ovarian cancer

Author Ilelis, Felipe Google Scholar
do Amaral, Nayra Soares Google Scholar
Alves, Mariana Rezende Google Scholar
Balieiro Anastacio da Costa, Alexandre Andre Google Scholar
Calsavara, Vinicius Fernando Google Scholar
Lordello, Leonardo Google Scholar
De Brot, Louise Google Scholar
Soares, Fernando Augusto Google Scholar
Rodrigues, Iara Sant'Ana Google Scholar
Rocha, Rafael Malagoli Autor UNIFESP Google Scholar
Abstract Aims: High grade serous carcinoma (HGSC) is an aggressive tumour, and most patients relapse after treatment, acquiring resistance to platinum-based chemotherapy. One of the resistance mechanisms proposed is apoptosis evasion triggered by drug-related cytotoxic effect in the cell. In this context, this study aims to evaluate the protein expression of GRIM-19, NF-kappa B and IKK2, their association with chemotherapy response and to determine their prognostic values in HGSC. & para;& para;Methods: GRIM-19, NF-kappa B and IKK2 expression was evaluated by immunohistochemistry (IHC) in 71 patients with HGSC selected between 2003 and 2013, whose underwent primary debulking surgery with complete cytoreduction. Protein expression was analyzed in relation to platinum response groups, tumour progression, clinicopathological data and survival. & para;& para

Results: Positive IKK2 expression was related to resistance (p = 0.011), shorter disease-free survival (p = 0.001) and overall survival (p = 0.026) and was also a risk factor for relapse (p = 0.002) and death (p = 0.032). The association between IKK2 and NF-kappa B positivity predicted a subgroup with shorter overall survival (p = 0.004), disease-free survival (p = 0.003) and resistance to platinum-based chemotherapy (p = 0.036). NF-kappa B positivity was associated with worse overall survival (p = 0.005) and disease-free survival (p = 0.027) and was a positive predictor for relapse (p = 0.032) and death (p = 0.008). Higher expression of GRIM-19 was associated with higher disease-free survival (p = 0.039) and was a negative predictor for relapse (p = 0.046). & para;& para;Conclusions: GRIM-19 is a potential predictor of prognosis and disease recurrence in HGSC. IKK2 and NF-kappa B are related to poor prognosis and are potential predictors of response to platinum-based chemotherapy in HGSC. IHC analyses of GRIM19, IKK2 and NF-kappa B may be important in the attempt to provide prognostic values for relapse and response to treatment in patients with HGSC.
Keywords Immunohistochemistry
Serous cystadenocarcinoma
Ovarian neoplasms
xmlui.dri2xhtml.METS-1.0.item-coverage Jena
Language English
Sponsor Sao Paulo Research Foundation (FAPESP)
Coordination for the Improvement of Higher Educational Personnel (CAPES)
Date 2018
Published in Pathology Research And Practice. Jena, v. 214, n. 2, p. 187-194, 2018.
ISSN 0344-0338 (Sherpa/Romeo, impact factor)
Publisher Elsevier Gmbh, Urban & Fischer Verlag
Extent 187-194
Access rights Closed access
Type Article
Web of Science ID WOS:000429085800002

Show full item record


File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)




My Account